Lemaitre Vascular Inc’s filing revealed that its Director Lawrence J. Jasinski acquired Company’s shares for reported $90553.0 on Aug 12 ’25. In the deal valued at $92.78 per share,976 shares were bought.
Then, JOHN ADAM ROUSH bought 6,561 shares, generating $607,230 in total proceeds.
Before that, DAVID ROBERTS bought 10,815 shares. Lemaitre Vascular Inc shares valued at $999,173 were divested by the Officer at a price of $92.39 per share.
Barrington Research upgraded its Lemaitre Vascular Inc [LMAT] rating to an Outperform from a a Mkt perform in a research note published recently. A number of analysts have revised their coverage, including Oppenheimer’s analysts, who decreased its forecast for the stock in late February from “an Outperform” to “a Perform”. Barrington Research also remained covering LMAT and has decreased its forecast on February 28, 2025 with a “Mkt perform” recommendation from previously “an Outperform” rating. Wells Fargo started covering the stock on February 13, 2025. It rated LMAT as “an Equal weight”.
Price Performance Review of LMAT
On Tuesday, Lemaitre Vascular Inc [NASDAQ:LMAT] saw its stock jump 1.90% to $94.38. Over the last five days, the stock has gained 10.26%. Lemaitre Vascular Inc shares have risen nearly 13.81% since the year began. Nevertheless, the stocks have risen 2.43% over the past one year. While a 52-week high of $109.58 was reached on 02/26/25, a 52-week low of $71.42 was recorded on 04/07/25.
Levels Of Support And Resistance For LMAT Stock
The 24-hour chart illustrates a support level at 92.69, which if violated will result in even more drops to 90.99. On the upside, there is a resistance level at 95.24. A further resistance level may holdings at 96.09.
How much short interest is there in Lemaitre Vascular Inc?
A steep rise in short interest was recorded in Lemaitre Vascular Inc stocks on 2025-07-31, dropping by -0.12 million shares to a total of 1.33 million shares. Yahoo Finance data shows the prior-month short interest on 2025-06-30 was 1.46 million shares. There was a decline of -9.37%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on October 15, 2024 when Cantor Fitzgerald began covering the stock and recommended ‘”a Neutral”‘ rating along with a $96 price target.
